CASE STUDY Implementing Innovative Strategies to Deliver a Complex Phase I Psoriasis Study Exceptional Support Drives Multi-national EnrollmentImplementing Innovative Strategies to Deliver a Complex Phase I Psoriasis Study Exceptional Support Drives Multi-national Enrollment Regions Central Europe Eastern Europe STUDY DESCRIPTION Multicenter, Phase I, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of multiple ascending doses of subcutaneous investigational medicinal product (nanobody) in males and females. A top pharma company approached PRA to conduct a complex multinational Phase I multiple ascending dose study in patients with moderate to severe chronic plaque psoriasi

Join for free to read